title: Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
authors.forename: J
authors.initials: J
authors.lastname: Ayllon
authors.forename: V
authors.initials: V
authors.lastname: Launay-Vacher
authors.forename: J
authors.initials: J
authors.lastname: Medioni
authors.forename: C
authors.initials: C
authors.lastname: Cros
authors.forename: J P
authors.initials: JP
authors.lastname: Spano
authors.forename: S
authors.initials: S
authors.lastname: Oudard
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007571:Jaw Diseases / Q000139:chemically induced*; D010020:Osteonecrosis / Q000139:chemically induced*; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D000077211:Zoledronic Acid
chemical_list: D020533:Angiogenesis Inhibitors; D004164:Diphosphonates; D007093:Imidazoles; D007211:Indoles; D011758:Pyrroles; D000077211:Zoledronic Acid; D000077210:Sunitinib